characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic hiv-1 gag vaccine trial最初的病毒抑制的特点和结果分析治疗期间中断治疗hiv - 1的呕吐疫苗试验.pdfVIP

Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial 1,2 3 4 3,5 6 Jonathan Z. Li *, Chanson J. Brumme , Michael M. Lederman , Zabrina L. Brumme , Hongying Wang , 6 3,7 4 2,3,8 9 John Spritzler , Mary Carrington , Kathleen Medvik , Bruce D. Walker , Robert T. Schooley , Daniel R. Kuritzkes1,2, for the AIDS Clinical Trials Group A5197 Study Team 1 Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 2 Harvard Medical School, Boston, Massachusetts, United States of America, 3 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, United States of America, 4 Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America, 5 Simon Fraser University, Burnaby, British Columbia, Canada, 6 Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America, 7 Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc., NCI Frederick, Frederick, Maryland, United States of America, 8 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, 9 Division of Infectious Diseases, University of California San Diego, La Jolla, California, United States of America Abstract Background: In the placebo-controlled trial ACTG A5197, a trend favoring vira